@article{oai:nagasaki-u.repo.nii.ac.jp:00009481,
 author = {泉川, 公一 and 河野, 茂},
 issue = {2},
 journal = {Drug Delivery System},
 month = {Jun},
 note = {The number of deep-seated mycosis cases is increasing rapidly along with the extreme advanced technology and highly sophisticated treatment. High mortality of deep-seated mycosis is critical concern, and an appropriate strategy and usage of antifungals is extremely important. The increasing potential efficacy of antifungals using the technology of drug delivery system is one of the reasonable strategies for improving the outcome of these patients with fungal infection. The development of liposomal amphotericin B using liposome is considered as a successful model case of development of newer drugs to improve the potential antifungal activity and reduce the cytotoxic effect using drug delivery system. Other newer antifungal drugs using a variety of drug delivery technology are currently being developed and numerous studies are underway. The main aim of this review is to introduce these developing drugs and the future of management of deep-seated mycosis., 医療技術の進歩に伴い日和見感染症は増加の一途にある。中でも深在性真菌症は致死的な感染症でその治療はきわめて重要である。種類の限られた抗真菌薬をDDSにてさらに改良し、予後を改善することは、予後不良な深在性真菌症では最も求められる。アムホテリシンBは最も古典的な薬剤であるが、副作用のために使用が困難な薬剤であり、DDS技術の応用で脂質製剤が登場し、DDS応用が成功したモデルケースの1つと考えられる。現在も、新たな技術を駆使した様々なDDS製剤が開発、研究されている。1つでも多くの薬剤が登場することを期待する。, Drug Delivery System, 27(2), pp.93-105; 2012},
 pages = {93--105},
 title = {深在性真菌症に対するDDS},
 volume = {27},
 year = {2012}
}